https://scholars.lib.ntu.edu.tw/handle/123456789/567247
標題: | Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study | 作者: | CHIEN-CHIA SU Chen J.Y.-C. Wang T.-H. JEHN-YU HUANG CHUNG-MAY YANG I-JONG WANG |
關鍵字: | Age-adjusted Charlson comorbidity index; Depression; Glaucoma | 公開日期: | 2015 | 出版社: | Springer Verlag | 卷: | 253 | 期: | 8 | 起(迄)頁: | 1319-1325 | 來源出版物: | Graefe's Archive for Clinical and Experimental Ophthalmology | 摘要: | Purpose: The purpose was to investigate the risk factors for depressive symptoms in glaucoma patients. Methods: From the Longitudinal Health Insurance Database in Taiwan, we included 1190 glaucoma patients with subsequent depression diagnoses in the case group and randomly selected 4673 glaucoma patients without depression diagnoses as the control group, matched by age, sex, and time of glaucoma diagnosis. The age-adjusted Charlson comorbidity index (ACCI) score was used to compute the burden of comorbidity for each patient. Current use (past 6?months) of topical antiglaucoma medications and systemic medications was identified. Multivariate regression was used to analyze the risk factors for depression. Results: The mean age for glaucoma patients was 61.88?years. Patients with depressive symptoms had significantly higher ACCI scores (P <.0001). The current use of any topical antiglaucoma medications was not associated with an increased risk for depression. However, higher ACCI scores (P <.0001), cerebrovascular diseases (odds ratio [OR] = 1.324, 95?% confidence interval [CI] = 1.118--1.568), dementia (OR = 2.647, 95?% CI = 2.142–3.270), thyroid diseases (OR = 1.720, 95?% CI = 1.366–2.165), headaches (OR = 1.299, 95?% CI = 1.112–1.518), and current use of systemic β-blockers (OR = 1.782, 95?% CI = 1.538–2.065) and calcium channel blockers (OR = 1.396, 95?% CI, 1.197–1.629) were found to increase the risk of depression in glaucoma patients. Conclusions: In this study, a comorbidity burden was a significant risk factor for depression in glaucoma patients, particularly for those currently using systemic β-blockers and calcium channel blockers. ? 2015, Springer-Verlag Berlin Heidelberg. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938415552&doi=10.1007%2fs00417-015-3032-0&partnerID=40&md5=0aa505db9b575e08ea651f6fa3ad775d https://scholars.lib.ntu.edu.tw/handle/123456789/567247 |
ISSN: | 0721-832X | DOI: | 10.1007/s00417-015-3032-0 | SDG/關鍵字: | adrenergic receptor stimulating agent; antiglaucoma agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; carbonate dehydratase inhibitor; cholinergic receptor stimulating agent; prostaglandin derivative; antihypertensive agent; adult; age adjusted charlson comorbidity index; Article; cerebrovascular disease; Charlson Comorbidity Index; chronic kidney disease; chronic obstructive lung disease; comorbidity; congestive heart failure; controlled study; dementia; depression; diabetes mellitus; drug use; female; glaucoma; headache; human; hypertension; major clinical study; male; middle aged; peripheral vascular disease; population based case control study; priority journal; risk factor; systemic therapy; thyroid disease; topical treatment; aged; Cardiovascular Diseases; case control study; Cerebrovascular Disorders; Depressive Disorder; Diabetes Complications; factual database; glaucoma; hypertension; odds ratio; Peripheral Vascular Diseases; risk factor; Taiwan; Adult; Aged; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Cerebrovascular Disorders; Comorbidity; Databases, Factual; Depressive Disorder; Diabetes Complications; Female; Glaucoma; Humans; Hypertension; Male; Middle Aged; Odds Ratio; Peripheral Vascular Diseases; Risk Factors; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。